A Study of Chidamide With AZA in MRD Positive AML After Transplant
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorGuangdong Provincial People's Hospital
About this trial
acute myeloid leukemia (AML) is a malignant tumor of the hematopoietic system with high heterogeneity in cytogenetics and molecular biology.Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is still the primary treatment option for patients with AML and the most effective method for radical treatment of AML.Despite considerable progress in allo-HSCT over the past decade, 30%-40% of patients still relapse, and post-transplant relapse remains the leading cause of death in patients with AML.
Eligibility criteria
Qualifiers
Patients diagnosed with AML (diagnostic criteria refer to WHO2016 criteria, except M3) can detect small residual lesions (MRD) positive after allogeneic hematopoietic stem cell transplantation (allo-HSCT);
≥18 years old;
ECOG≤3;
lifespan≥3 months;
Disqualifiers
Allergic to the study drug;
A gastrointestinal condition that prevents oral medication;
active infection;
Dysfunction of vital organs;
Trial design
Treatments tested in this trial
- chidamide and azacitidine
Treatment groups
60 Participants
are divided into 1 treatment groupSponsors and collaborators
Guangdong Provincial People's Hospital
Lead sponsor
Chipscreen Biosciences, Ltd.
Collaborator
Source ClinicalTrials.gov